¡¡¡¡Ïã¼ÓƤÌáÈ¡ÎÖ×Áö¼°ÃâÒßµ÷½Ú×÷ÓõÄʵÑéÑо¿
ºÓ±±Ò½¿Æ´óѧµÚËÄÒ½Ôº¿ÆÑÐÖÐÐÄ ÕÔÁ¬Ã·
¡¾ÕªÒª¡¿Ä¿µÄ£ºÑо¿ÖÐÒ©Ïã¼ÓƤÁ½ÖÖÌáÈ¡ÎïµÄ¿¹Ö×ÁöºÍÃâÒßµ÷½Ú×÷ÓÃÒÔ¼°ËüÃǵÄ×÷ÓûúÖÆ£¬ÎªÖÎÁÆÊ³¹Ü°©Ñ°ÕÒÓÐЧҩÎͬʱΪÖÐÒ©Ïã¼ÓƤµÄ¶þ´Î¿ª·¢ÀûÓÃÌṩʵÑéÒÀ¾Ý¡£²ÄÁÏÓë·½·¨£º²ÉÓÃMTT·¨·ÖÎö²»Í¬Å¨¶ÈÏã¼ÓƤ¸ÜÁøÜÕ(CPP)×÷Óò»Í¬Ê±¼äºó£¬¶ÔËÄÖÖ¶ñÐԳ̶Ȳ»Í¬µÄʳ¹Ü°©Ï¸°ûÖêTE-13¡¢Eca-109¡¢TE-1¡¢TE-10ÔöÖ³·´Ó¦µÄÓ°Ïì¡£2. Óò»Í¬Å¨¶ÈCPP·Ö±ð´¦ÀíTE-13ϸ°û48hºó£¬²ÉÓÃGimsaȾɫ¼¼ÊõºÍÁ÷ʽϸ°û¼¼Êõ¼ì²âϸ°ûµòÍöºÍϸ°ûÖÜÆÚ·Ö²¼Çé¿ö¡£3. ²ÉÓÃWestern blot¼¼Êõ·ÖÎöϸ°ûÖÜÆÚµ°°×ÒÀÀµÐÔ¼¤Ã¸CDK2ºÍCDK4µÄ±í´ï±ä»¯£¬ÒÔ̽ÌÖCPPÓÕµ¼Ï¸°ûµòÍö¼°Ï¸°ûÉú³¤ÖÜÆÚ×èÖ͵ĿÉÄÜ»úÖÆ¡£4. ²ÉÓÃRT-PCR·¨·ÖÎöËÄÖÖʳ¹Ü°©Ï¸°ûÖêTE-13¡¢ Eca- 109¡¢TE-1ºÍTE-10 syk mRNAµÄ±í´ï״̬£¬ÒÔ¼°¾CPP ´¦Àíºósyk mRNA±í´ïµÄ¸Ä±äÇé¿ö£¬Í¬Ê±²ÉÓÃÁ÷ʽϸ°û¼¼Êõ·ÖÎöCPP´¦Àíϸ°ûǰºóϸ°ûÖÐsykµ°°×±í´ïµÄ±ä»¯¡£5. ÎÞ¾ú·ÖÀ뽡¿µÈËÍâÖÜѪÁܰÍϸ°û£¬MTT·¨·ÖÎö²»Å¨¶ÈÏã¼ÓƤÓðÉȶ¹ÍéÒÒËáõ¥(CPLA)¶ÔÈËÍâÖÜѪÁܰÍϸ°ûÔöÖ³ºÍ¶Ô¾ÞÊÉϸ°ûÍÌÊɹ¦ÄܵÄÓ°Ï죬6. ÓÃELISAºÍRT-PCR·¨·ÖÎöCPLA¶ÔÈËÍâÖÜѪÁܰÍϸ°û²úÉúϸ°ûÒò×Ó¹¦ÄܵÄÓ°Ïì¡£½á¹û£º1.Ïã¼ÓƤÌáÈ¡Îï¸ÜÁøÜÕ(CPP)ÌåÍâ¶Ô¶ñÐԳ̶Ȳ»Í¬µÄʳ¹Ü°©Ï¸°ûTE-13¡¢Eca-109¡¢TE-1¡¢TE-10µÄÔöÖ³·´Ó¦¾ùÓÐÏÔÖøÒÖÖÆ×÷ÓÃ(P<0.01); 2. CPP×÷ÓÃÓÚÖ×Áöϸ°ûºó£¬¿ÉÓÕµ¼µäÐ͵Äϸ°ûµòÍöÐÎ̬±ä»¯; Á÷ʽϸ°û·ÖÎö½á¹ûÏÔʾ£¬CPPÄÜʹTE-13ϸ°û·¢ÉúµòÍöºÍÖÜÆÚ×èÖÍ£¬´¦Àí48hʱ£¬µòÍöÂÊÃ÷ÏÔÔö¼Ó£»G0/G1ϸ°ûÃ÷ÏÔÔö¼Ó£¬SÆÚϸ°ûÃ÷ÏÔ¼õÉÙ£¬Óë¶ÔÕÕ×éÏà±È£¬²îÒìÓÐÏÔÖøÐÔ(P<0.01)¡£3.CPPÄܹ»Ê¹TE-13ϸ°ûCDK4µ°°×±í´ïˮƽÃ÷ÏÔϵ÷£¬Óë¶ÔÕÕ×éÏà±È£¬²îÒìÓÐÏÔÖøÐÔ(P<0.01)¡£CPP¶ÔCDK2µÄµ°°×±í´ïûÓÐÃ÷ÏÔÓ°Ïì(P>0.05); 4.RT-PCR·¨·ÖÎö½á¹ûÏÔʾ¸ß¶È¶ñÐÔµÄϸ°ûÖêTE-13¡¢Eca-109 syk mRNA(514bp)±í´ïÈõÑôÐÔ£¬¶ñÐԳ̶ȱȽϵ͵Äʳ¹Ü°©Ï¸°ûÖêTE-1syk mRNA±í´ïˮƽÃ÷ÏÔ¸ßÓÚTE-13¡¢Eca-109ϸ°û£¬¶øÔÚ¶ñÐԳ̶ȱȽϵ͵Äʳ¹Ü°©Ï¸°ûÖêTE-10ÖÐȴδ¼ì²âµ½syk mRNAµÄ±í´ï¡£¾CPP´¦Àíºó£¬TE-13¡¢Eca-109¡¢TE-1 syk mRNA±í´ïÔöÇ¿, ¶ÔTE-10ϸ°ûsyk mRNA±í´ïûÓÐÓ°Ïì(P>0.05)¡£Á÷ʽϸ°û¼¼ÊõÏÔʾÉÏÊöϸ°ûsykµ°°×±í´ïˮƽ½á¹ûÓëmRNA±í´ïÇé¿öÏà·ûºÏ¡£5.Ïã¼ÓƤÌáÈ¡ÎïÓðÉȶ¹ÍéÒÒËáõ¥(CPLA)ÄÜÃ÷ÏÔ´Ù½øPHA»î»¯µÄÈËÍâÖÜѪÁܰÍϸ°ûµÄÔöÖ³ÒÔ¼°ÍÌÊÉϸ°ûµÄÍÌÊÉ×÷ÓÃ; 6. ELISA¼ì²â½á¹ûÏÔʾ£¬¾CPLA×÷Óúó£¬ÈËÍâÖÜѪÁܰÍϸ°û²úÉúTNF-¦ÁºÍIL-2ˮƽÏÔÖøÉý¸ß(P<0.01)¡£RT-PCR·ÖÎö½á¹ûÏÔʾ£¬20¦Ìg/mlºÍ40¦Ìg/ml CPLA´¦Àíºó£¬ÄÜÃ÷ÏÔÔöÇ¿ PHAµÄ»î»¯×÷Óã¬Ê¹ÁܰÍϸ°ûIFN-¦Ã mRNAµÄ±í´ïˮƽÃ÷ÏÔÔöÇ¿(P<0.01)¡£½áÂÛ£ºÏã¼ÓƤÌáÈ¡Îï¸ÜÁøÜÕ(CPP)ÌåÍâÄÜÃ÷ÏÔÒÖÖÆÊ³¹Ü°©Ï¸°ûµÄÔöÖ³; CPP¶Ôʳ¹Ü°©Ï¸°ûTE-13µÄÒÖÖÆ×÷ÓÿÉÄÜÓëÆäÓÕµ¼Ï¸°ûµòÍöºÍϸ°ûÖÜÆÚ×èÖÍÓйأ¬CPPÄÜʹTE-13ϸ°ûµÄÉú³¤ÖÜÆÚ×èÖÍÔÚG0/G1ÆÚ£¬Æä»úÖÆ¿ÉÄÜÓëCPPϵ÷ϸ°ûÖÜÆÚµ°°×ÒÀÀµÐÔ¼¤Ã¸CDK4µÄ±í´ïÓйØ; CPPµÄÒÖÁö×÷ÓÿÉÄÜ»¹ÓëÆä»Ö¸´ºòÑ¡ÒÖ°©»ùÒòsyk mRNAºÍµ°°×µÄ±í´ïÓйأ¬±íÃ÷CPP·¢»ÓÒÖÁö×÷ÓÃÊǶà»ùÒò¡¢¶à°ÐµãµÄ; Ïã¼ÓƤÓðÉȶ¹ÍéÒÒËáõ¥(CPLA)³É·ÝÄÜÔöÇ¿ÈËÍâÖÜѪÁܰÍϸ°ûµÄÃâÒß¹¦ÄÜ£¬ÄÜ´Ù½øPHA»î»¯µÄÁܰÍϸ°ûÔöÖ³£»CPLAÄÜÔöÇ¿ÍÌÊÉϸ°û¶ÔÖ×Áöϸ°ûµÄɱÉ˹¦ÄÜ£¬Æä»úÖÆ¿ÉÄÜÓëCPLAÄÜ´Ù½øÍÌÊÉϸ°û²úÉúTNF-¦ÁÓйØ; CPLAÄÜ´Ù½øÍâÖÜѪÁܰÍϸ°û²úÉúTNF-¦ÁºÍIL-2µÈϸ°ûÒò×Ó£¬²¢ÄÜÔöÇ¿ÍâÖÜѪÁܰÍϸ°ûIFN-¦Ã mRNAµÄ±í´ï¡£
¡¡¡¡Exprimental study on the Antineoplastic Activity and Immunoregulatory Activity of cortex periplocae extracts
¡¡¡¡[Abstruct] Objective: In order to study antitumor and Immuno -regulation mechanism of both different extracts of cortex periplocae, which are helpful for finding the effective therapeutic measures for curing of human esophageal carcinoma. Meanwhile, which provide us with some experimental bases to develop and exploite Chinese medicine herb of cortex periplocae. Methods: 1. MTT assays was used to detect the suppressive effect of CPP on different human esophageal carcinoma cells such as TE-13, Eca-109, TE-1 and TE-10. 2. Affter treatment with CPP for 48h, The cycle and apoptosis of human esophageal carcinma cells TE-13 was studied by flow-cyto -metry (FCM); 3. Expression of CDK2 and CDK4 were detected with western blot. 4. The expression of syk mRNA in four kinds of human esophageal carcinma cells line and the changes of syk mRNA induced by CPP were analyzed by RT-PCR, and the changes of syk protein was measured by FCM; 5. Lymphocytes from human peripheral blood were isolataed by density gradient centrifugation with lymphocyte isolation. Effect of CPP on proliferation of lymphocytes and phogocitoxity to macrophages on carcinoma cells were studied wit MTT; 6. The influence of CPLA on cytokines production by lymphocytes was analyzed with ELISA and RT-PCR. Results: CPP inhibited the proliferation of human esophageal carcinoma cells such as TE-13, Eca-109, TE-1 and TE-10 in a time and dose-dependent manner(P<0.01); After treatment with CPP, TE-13 cells shown some typical morphologic features; The result of FCM showed that CPP can induce apoptosis and cell cycle of TE-13 cells; TE-13 cells cycle arresting induced by CPP may be related with CDK4 protein decreaing, but it have no relate with CDK2 protein expression; Expression level of syk mRNA in TE-13 and Eca-109 are very lowly, while the expression level of syk mRNA was high in TE-1 cell and was negative in TE-10 cell; After treatment with CPP for 48h, the expression of syk mRNA(514bp) in TE-13¡¢Eca-109 and TE-1 increase markly, but CPP have no effect on that in TE-10 cells.The result of syk protein measured by FCM are consistent with the FCM result; The proliferation of lymphocytes was enhanced by 5¦Ìg/ml-40¦Ìg/ml CPLA with acting of PHA, and in a dose dependent manner(p<0.01); CPLA(5-40¦Ìg/ml) can strengthen the phagocytosis effect of macrophage on esophageal carcinoma cells significantly(p< 0.01); The production of IL-2 and TNF-¦Á by lymphocytes could be augmented by treatment with CPLA significantly, which is in a dose-dependment (P<0.01); The expression of IFN-¦Ã mRNA in lymphocytes was also enhanced by 20¦Ìg/ml and 40¦Ìg/ml CPLA. Conclusions: 1. CPP showed very strong inhibitory effect on the proliferation of esophague carcinoma cells such as TE-13¡¢Eca-109, TE-1 and TE-10 cells; Inhabitory effect of CPP on TE-13 cells can be related to induce apoptosis of cells and arrest of cell cycle at G0/G1, and it may be related with CDK4 protein expressin and have no related with CDK2 protein expression; Syk mRNA and protein expression in human esophageal carcinoma cells are low and it can be enhanced by CPP; The results showed that inhabitory effect of CPP on human esophageal carcinoma cells have relation with syk up-regulation; The proliferation of lymphocytes was enhanced by CPLA, which also can strengthen macrophage to inhabit the proliferation of esophageal carcinoma cells significantly. The production of several tumor immunity-related cytokines can be augmented by treatment with CPLA.
|